AI drug discovery: benchmark flaws may distort leaderboards, as CIOMS issues pharmacovigilance validation standards
An article reports that benchmark flaws may be distorting AI drug-discovery leaderboards (27 August). The CIOMS Working Group XIV has released validation standards for the use of AI in pharmacovigilance.
Who is affected and how
- pharmaceuticals
- Vendor claims based on benchmarks should be verified independently; a validation standard is now available for pharmacovigilance AI.
- health policy
- The CIOMS standard could serve as a basis for regulatory expectations on pharmacovigilance AI.
Sources
- Benchmark flaws may be distorting AI drug-discovery leaderboardschemistry world · Aug 27, 2026
- Benchmark flaws may be distorting AI drug-discovery leaderboards | Research | Chemistry Worldchemistryworld.com · Aug 27, 2026
- AI Reveals Cancer Drug Combinations - Biohubbiohub.org · Aug 26, 2026
- AI Reveals Cancer Drug Combinations · GlioStategliostate.com · Aug 26, 2026
- CIOMS Working Group XIV Releases Validation Standards for AI in Pharmacovigilance - GeneOnline Newsgeneonline.com · Aug 27, 2026
- AI Validation in Pharmacovigilance: New Standardspharmafocuseurope.com · Aug 28, 2026
- Nature Biotechnology | Aureka Wins the Global Blinded AI Antibody Benchmark: AI Design Surpasses the Best Experimental Result - us.acrofan.comus.acrofan.com · Aug 27, 2026 · magyar
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.